FDA Accepts UCB’s sBLA for Bimzelx in HS
https://vimeo.com/937443081 The U.S. Food and Drug Administration (FDA) recently accepted UCB’s supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin (IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Jeffrey Stark, MD, VP and Head of Medical Immunology, UCB, discusses the data supporting the sBLA and the […]